US20040162327A1 - Crystalline form of telmisartan sodium - Google Patents

Crystalline form of telmisartan sodium Download PDF

Info

Publication number
US20040162327A1
US20040162327A1 US10/777,304 US77730404A US2004162327A1 US 20040162327 A1 US20040162327 A1 US 20040162327A1 US 77730404 A US77730404 A US 77730404A US 2004162327 A1 US2004162327 A1 US 2004162327A1
Authority
US
United States
Prior art keywords
telmisartan
sodium
solvent
crystalline
sodium salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/777,304
Inventor
Kai Donsbach
Irmgard Hof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE10153737A priority Critical patent/DE10153737A1/en
Priority to DEDE10153737.9 priority
Priority to US35144302P priority
Priority to US10/283,440 priority patent/US6737432B2/en
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to US10/777,304 priority patent/US20040162327A1/en
Publication of US20040162327A1 publication Critical patent/US20040162327A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical

Abstract

The invention relates to a crystalline sodium salt of 4′-[2-n-propyl-4-methyl-6-(1-methyl-benzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), processes for preparing it and the use thereof for preparing a pharmaceutical composition.

Description

    RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 10,283,440, filed Oct. 30, 2002, which claims, as does the present application priority to U.S. Provisional Application Serial No. 60/351,443, filed on Jan. 24, 2002, the disclosures of all of which are incorporated by reference in their entirety.[0001]
  • FIELD OF THE INVENTION
  • The invention relates to a crystalline form of the sodium salt of telmisartan, processes for preparing it and the use thereof for preparing a pharmaceutical composition. [0002]
  • BACKGROUND OF THE INVENTION
  • Telmisartan is the nonproprietary name (INN, USAN and BAN) for 4′-[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid. It has the following chemical structure [0003]
    Figure US20040162327A1-20040819-C00001
  • and is known from European Patent EP 502 314 B1 and U.S. Pat. No. 5,591,762. [0004]
  • Telmisartan, and the physiologically acceptable salts thereof, have valuable pharmacological properties. Telmisartan is an angiotensin antagonist, particularly an angiotensin-II-antagonist which by virtue of its pharmacological properties may be used for example to treat hypertension and cardiac insufficiency, to treat ischaemic peripheral circulatory disorders, myocardial ischaemia (angina), to prevent the progression of cardiac insufficiency after myocardial infarct, to treat diabetic neuropathy, glaucoma, gastrointestinal diseases and bladder diseases. Other possible therapeutic applications can be found in EP 502314 B1 and U.S. Pat. No. 5,591,762. [0005]
  • A pharmaceutical formulation comprising telmisartan as the active ingredient, Micardis® (telmisartan) Tablets, is commercially available. [0006]
  • Starting from the free acid of telmisartan, the preparation in the form in which telmisartan is marketed is produced by a complex spray drying process. Because of the limited solubility of the free acid, less complex methods of preparing an alternative preparation are difficult to achieve. [0007]
  • Thus, one objective of the present invention is to find a less complex and easier means for preparing a crystalline form of telmisartan that would be suitable for use in the preparation of pharmaceutical formulations. [0008]
  • It has to be borne in mind that generally the production of a composition containing a pharmaceutically active substance is based on various parameters which are linked to the nature of the active ingredient itself. Without being tied thereto, examples of these parameters are the stability of effect of the starting material under different environmental conditions, the stability during the manufacture of the pharmaceutical formulation and the stability in the final compositions of the pharmaceutical preparation. The pharmaceutically active substance used to prepare the abovementioned pharmaceutical compositions should be as pure as possible and its stability on long-term storage must be guaranteed under various environmental conditions. This is absolutely essential, in order to prevent pharmaceutical compositions being used which contain, in addition to the active substance proper, breakdown products thereof. In such a case the content of active substance present in a preparation produced therefrom may be less than the specified amount. [0009]
  • Another aspect which is important in the production of solid preparations is that the active substance should have the most stable possible crystalline morphology for pharmaceutical quality. If this is not the case, the morphology of the active substance may change in certain circumstances under the conditions of manufacture of the preparation. Such a change may in turn affect the reproducibility of the manufacturing process and thus lead to final formulations which do not meet the high quality requirements imposed on formulations of pharmaceutical compositions. To this extent it should be generally borne in mind that any change to the solid state of a pharmaceutical composition which can improve its physical and chemical stability gives a significant advantage of less stable forms of the same drug. [0010]
  • Thus, a further object of the invention is to provide a new, stable, crystalline form of telmisartan which complies with the abovementioned stringent requirements imposed on pharmaceutically active substances.[0011]
  • BRIEF DESCRIPTION OF THE FIGURE
  • FIG. 1: X-ray powder diagram of telmisartan-sodium salt[0012]
  • DETAILED DESCRIPTION OF THE INVENTION
  • Surprisingly, it has been found that telmisartan can be obtained in crystalline form, as the sodium salt of the below formula 1. [0013]
    Figure US20040162327A1-20040819-C00002
  • In accordance with conventions respecting the use of nonproprietary names, the telmisartan salt of formula 1 may be referred to as telmisartan sodium. Therefore, as used herein, the term “telmisartan sodium” is defined to mean the telmisartan salt of formula 1. [0014]
  • By a suitable choice of manufacturing conditions, the polymorphic form of the crystalline sodium salt which meets the requirements mentioned above can be obtained selectively. [0015]
  • This crystalline form of the sodium salt of telmisartan is characterised by having a melting point of T=245±5° C. (determined by DSC=Differential Scanning Calorimetry; heating rate: 10 K/min). [0016]
  • The present invention therefore relates to a crystalline form of telmisartan sodium that is characterised by having a melting point of T=245±5° C. (determined by DSC). The above value was obtained using a DSC821 made by Messrs Mettler-Toledo. [0017]
  • The crystalline form of telmisartan sodium according to the invention was examined more closely by x-ray powder diffraction. The X-ray powder diagram obtained is shown in FIG. 1. [0018]
  • The following Table 1 summarizes the data obtained in this x-ray powder diffraction analysis: [0019] TABLE 1 2 Θ [°] d [Å] rel. intensity [%] 3.54 24.96 7 4.21 20.95 100 4.45 19.83 20 4.98 17.72 54 5.69 15.52 8 6.32 13.97 34 6.48 13.63 35 7.12 12.41 12 7.49 11.80 11 8.08 10.93 4 8.49 10.41 6 8.96 9.86 7 9.50 9.31 5 10.19 8.68 5 10.80 8.18 8 11.16 7.92 18 11.88 7.44 7 12.51 7.07 7 12.79 6.92 11 13.17 6.72 7 13.68 6.47 7 14.36 6.16 10 14.98 5.91 13 15.51 5.71 14 15.70 5.64 12 16.21 5.46 8 17.09 5.18 10 17.48 5.07 9 18.10 4.90 9 19.18 4.62 11 19.43 4.56 13 19.95 4.45 11 20.89 4.25 11 21.29 4.17 10 22.19 4.00 9 23.07 3.85 10 23.76 3.74 9 24.43 3.64 8
  • In the above Table the value “2 Θ [°]” denotes the angle of diffraction in degrees and the value “d [Å]” denotes the lattice plane spacings determined in Å. [0020]
  • According to the findings given in Table 1, the crystalline form of telmisartan sodium that constitutes the invention is characterised in that, when subjected to analysis by x-ray powder diffraction, it exhibits a characteristic set of d-spacings that includes values at d=20.95 Å, 17.72 Å, 13.97 Å and 13.63 Å. [0021]
  • The X-ray powder diagrams were recorded within the scope of the present invention using a Bruker D8 Advanced with an SSD (=site-sensitive detector) (CuK[0022] α—radiation, λ=1.5418 Å, 30 kV, 40 mA).
  • The present invention also comprises the solvates and hydrates of the above-described crystalline form of telmisartan sodium, especially the hydrates, most especially the hemihydrate thereof. [0023]
  • In another aspect, the present invention comprises a method of producing the crystalline form of telmisartan sodium according to the invention. The starting material used to prepare the crystalline telmisartan sodium according to the invention may be the free acid of telmisartan, which may be obtained by methods known in the art (e.g. according to EP 502314 A1 and U.S. Pat. No. 5,591,762). [0024]
  • To prepare the crystalline telmisartan sodium according to the invention the free acid of telmisartan is taken up in a suitable solvent, preferably in an organic aprotic solvent, most preferably in an organic, aprotic and non-polar solvent. The solvents used according to the invention are most preferably toluene, chloroform, dichloromethane, tetrahydrofuran, diethylether, diisopropylether, methyl-tert. butylether, acetone, methylisobutylketone, benzene or acetonitrile, of which toluene, benzene and methylisobutylketone are particularly preferred. Of outstanding importance according to the invention is toluene as solvent. [0025]
  • Preferably, between 0.5 and 5 ml, more preferably between 1 and 3 ml, most preferably between 1.5 and 2.5 ml of the abovementioned solvent are used per gram of telmisartan (free acid). [0026]
  • A suitable sodium salt is then added as a base to this solution or suspension. Suitable sodium salts within the scope of the present invention include sodium hydroxide, sodium hydride, sodium carbonate, sodium hydrogen carbonate or sodium alkoxides. By sodium alkoxides are meant the sodium salts which are formed with lower alcohols, preferably with alcohols selected from among methanol, ethanol, isopropanol, n-propanol, tert-butanol, sec.-butanol, isobutanol, n-butanol and tert.-amylalcohol. Of particular interest according to the invention are sodium salts selected from among sodium hydroxide, sodium hydride, sodium ethoxide and sodium methoxide; of these, sodium hydroxide and sodium methoxide are of particular importance according to the invention. The abovementioned sodium salts may be added to the reaction mixture as solids. In the case of sodium hydroxide this is preferably added in the form of aqueous solutions, however. It is particularly preferable to use concentrated aqueous solutions of sodium hydroxide. For example, sodium hydroxide solution may be used in a concentration of about 45 wt.-%. [0027]
  • The amount of sodium salt to be used naturally depends on the amount of free acid telmisartan used. According to the invention at least 1 mol of sodium salt has to be added per mol of telmisartan. It is also possible according to the invention to add an excess of sodium salt. Preferably, 1-2.5, more preferably 1-2, most preferably 1-1.5 mol of sodium salt are added per mol of the acid telmisartan used. [0028]
  • If sodium hydroxide is used as the sodium salt and this is added in the form of an aqueous solution, according to a preferred embodiment of the process according to the invention, it may be helpful in some cases to add a water-miscible organic solvent. This is preferably selected from among methanol, ethanol, isopropanol, acetone, tetrahydrofuran, tert.-butanol, 2-butanol, butanol, glycol, ethyldiglycol, 1,3-butanediol, 1,4-butanediol, tert.-amylalcohol, acetonitrile, nitromethane, formamide, dimethylformamide, N-methylpyrrolidinone, dimethylsulphoxide, dimethylacetamide, nitroethane and methoxy-2-propanol, of which the abovementioned alcohols are particularly significant. It is particularly preferred, within the scope of the process according to the invention, to use methanol or ethanol, most preferably ethanol. Preferably, between 50 and 500 ml, more preferably between 100 and 400 ml, most preferably between 200 and 350 ml of this solvent are used per mol of telmisartan used, according to the invention. [0029]
  • Then the reaction mixture may be heated to speed up the progress of the reaction. Preferably, the reaction mixture is heated to a temperature of >40° C., most preferably to over 60° C., with thorough mixing. The maximum temperature which may be selected is naturally determined by the boiling temperature of the solvents used. If the preferred solvents as described hereinbefore are used according to the invention, the mixture is preferably heated to over 70° C. This heating is generally carried out for a period of from 15 minutes to 2 hours, preferably between 20 minutes and one hour. Then the solution obtained is filtered and any solid remaining in the filter is washed with one or more of the abovementioned solvents. [0030]
  • The filtrate obtained by the process described above is added slowly, preferably dropwise, to an organic solvent which is heated to a temperature of >40° C., preferably above 60° C., most preferably to boiling point. The solvent used is preferably an organic aprotic solvent, more preferably an organic, aprotic and non-polar solvent. Solvents which may be used according to the invention are, most preferably, toluene, chloroform, dichloromethane, tetrahydrofuran, diethylether, diisopropylether, methyl-tert, butylether, acetone, methylisobutylketone, benzene or acetonitrile, of which toluene, benzene and methylisobutylketone are particularly preferred. The solvent toluene is of exceptional importance according to the invention. At the same time as the filtrate is added to the heated solvent, in a preferred embodiment of the invention, some of the solvent is distilled off (optionally azeotropically). After all the filtrate has been added, more solvent (e.g. about one to two thirds of the total amount of solvent added by this stage) may optionally be removed by distillation. [0031]
  • The concentrated solution thus obtained is cooled, preferably to ambient temperature, whereupon the telmisartan sodium salt crystallises out. After crystallisation is complete the crystals are separated off, optionally washed with the organic solvent mentioned above and finally dried. [0032]
  • In another embodiment of the invention the crystalline telmisartan sodium salt according to the invention may be obtained starting from the acid addition salts of formula 2 [0033]
    Figure US20040162327A1-20040819-C00003
  • wherein H—X denotes an acid selected from among hydrochloric acid, hydrobromic acid, toluenesulphonic acid or methanesulphonic acid. Of the abovementioned acid addition salts of formula 2 the salt wherein H—X denotes hydrochloric acid is of particular significance. This acid addition salts is also referred to hereinafter as telmisartan hydrochloride. [0034]
  • The compounds of formula 2 may be obtained for example from tert.-butyl 4′-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate (=tert.-butyl ester of telmisartan) known from the prior art by saponification in acetic acid in the presence of the acid H—X. [0035]
  • In order to prepare the crystalline telmisartan sodium salt of formula 1 according to the invention starting from the acid addition salts of formula 2 the following procedure may be used, according to the invention. [0036]
  • The compound of formula 2 is taken up in a suitable solvent and combined with a suitable sodium salt. [0037]
  • The solvent may be water and/or a suitable alcohol, such as methanol, ethanol or isopropanol mixed with an aprotic organic solvent selected from among toluene, chloroform, dichloromethane, tetrahydrofuran, diethylether, diisopropylether, methyl-tert, butylether, acetone, methylisobutylketone, benzene and acetonitrile. It is particularly preferred to use, as the solvent, water mixed with ethanol or isopropanol mixed with an aprotic organic solvent selected from among toluene, benzene and methylisobutylketone, most preferably toluene. A mixture of water, isopropanol and toluene has proved particularly suitable for this step of the synthesis. [0038]
  • The amount of solvent or solvent mixture used depends on the amount of acid addition salt 2 used. Preferably, about 0.3-3.5 L, preferably about 1-2.5 L, more preferably about 1.5-2 L of the abovementioned solvent or solvent mixture are used per mol of compound 2 used. If the solvent used is the preferred solvent mixture according to the invention which contains an alcohol as the third solvent component in addition to water and an aprotic organic solvent, the ratios by volume of water to aprotic organic solvent according to the invention are preferably in a range from 1:5 to 1:50 and the ratio of water to alcohol used is in a range from 2:1 to 1:40. Preferably, in a solvent mixture of this kind, the ratios of water to aprotic organic solvent are in the range from 1:10 to 1:30, preferably in the range from 1:15 to 1:25 and the ratio of water to alcohol used is in a range from 1:1 to 1:20, preferably in the range from 1:5 to 1:15. [0039]
  • Preferably, the solvent or solvent mixture mentioned above contains about 10 to 100 ml of water, preferably about 30 to 80 ml of water, most preferably about 40 to 70 ml of water, per mol of 2. Preferably the solvent or solvent mixture used also contains about 100 to 1000 ml of alcohol, preferably about 300 to 800 ml alcohol, most preferably about 400 to 700 ml alcohol, per mol of 2. Finally, the solvent or solvent mixture used preferably contains as the third component of the solvent, about 200 to 2000 ml of the abovementioned aprotic organic solvent, preferably about 600 to 1600 ml, most preferably about 800 to 1400 ml of the abovementioned aprotic organic solvent, per mol of 2. [0040]
  • Suitable sodium salts which may be used for reacting 2 to I include sodium hydroxide, sodium hydride, sodium carbonate, sodium hydrogen carbonate or sodium alkoxides. By sodium alkoxides are meant the sodium salts which are formed with lower alcohols, preferably with alcohols selected from among methanol, ethanol, isopropanol, n-propanol, tert-butanol, sec.-butanol, isobutanol, n-butanol and tert.-amylalcohol. Of particular interest according to the invention are sodium salts selected from among sodium hydroxide, sodium hydride, sodium ethoxide and sodium methoxide, while the sodium alkoxides sodium ethoxide and sodium methoxide, particularly sodium methoxide are of particular importance according to the invention for this reaction step. The abovementioned sodium salts may be added to the reaction mixture as solids. In the case of sodium methoxide however it is preferable to add it in the form of a methanolic solution. Methanolic solutions of sodium methoxide which contain it in a concentration of at least 10%, most preferably about 20-40% (w/w) , are particularly preferred. For example, the methanolic sodium methoxide solution used may have a concentration of about 30 wt. %. [0041]
  • The amount of sodium salt to be used is naturally dependent on the amount of free acid telmisartan used. According to the invention, at least 2 mol of sodium salt have to be added per mol of telmisartan acid addition salt of formula 2 used. According to the invention it is also possible to add an excess of sodium salt. [0042]
  • It may be useful in some cases to add activated charcoal to the abovementioned reaction mixture. For example, it may be added in an amount of about 5-50 g per mol of 2 used, preferably in an amount of about 10-40 g per mol of 2 used. [0043]
  • After the sodium salt and optionally the activated charcoal has been added the reaction mixture obtained is heated to a temperature of about 50-100° C., preferably about 60-90° C., most preferably about 70-80° C. for a period of about 10 minutes to 2 hours, preferably for about 20-45 minutes. In the course of this heating, some of the solvent, preferably about 10-50%, most preferably about 20-40% of the total quantity of solvent may be distilled off. [0044]
  • The remaining suspension is then filtered, the filter residue is optionally washed with one of the abovementioned aprotic organic solvents, preferably with the aprotic organic solvent which is also used in the reaction. [0045]
  • The filtrate obtained is then diluted with a solvent or mixture of solvents. It is preferable to use a mixture of water and the abovementioned aprotic organic solvent for this. Preferably, at this point, about 10 to 100 ml of water, preferably about 30 to 80 ml of water, most preferably about 40 to 70 ml of water are used per mol of the compound 2 originally used. At this point, 250 to 3000 ml, preferably about 800 to 2000 ml, most preferably about 1200 to 1800 ml of aprotic organic solvent are used per mole of the compound 2 originally used. [0046]
  • After dilution, the mixture obtained is refluxed. Then about 1-2 L, preferably about 1200 to 1800 ml of solvent are distilled off per mole of the compound 2 originally used. After the solvent has been distilled off the telmisartan-sodium salt 1 according to the invention crystallises out. The crystals obtained are isolated, optionally washed with one of the abovementioned aprotic organic solvents and then dried. [0047]
  • In another aspect the present invention relates to crystalline telmisartan-sodium salt, optionally in the form of the solvates or hydrates thereof, preferably in the form of the hydrates thereof, most preferably in the form of the hemihydrate, which may be obtained by the methods described above. [0048]
  • Because of the central significance of the compounds of formula 2 as valuable starting materials for the direct synthesis of the telmisartan-sodium salt 1 according to the invention, in another aspect the present invention relates to compounds of formula 2 per se [0049]
    Figure US20040162327A1-20040819-C00004
  • wherein H—X denotes an acid selected from among hydrochloric acid, hydrobromic acid, toluenesulphonic acid or methanesulphonic acid. The compound of formula 2 wherein H—X denotes hydrogen chloride, the telmisartan hydrochloride, is particularly preferred. [0050]
  • Most preferably, the present invention further relates to the abovementioned compounds of formula 2 in crystalline form. [0051]
  • Moreover, in view of the pharmaceutical activity of the crystalline telmisartan sodium salt according to the invention, the present invention relates to the use thereof as a pharmaceutical composition. [0052]
  • In another aspect, in view of the pharmaceutical activity of the crystalline telmisartan sodium salt according to the invention, the present invention relates to the use thereof for preparing a pharmaceutical composition, particularly for preparing a pharmaceutical composition for the prevention or treatment of diseases wherein the administration of therapeutically effective doses of one or more angiotensin-II-antagonists may provide a therapeutic benefit. Preferably, the present invention relates to the use of crystalline telmisartan-sodium salt for preparing a pharmaceutical composition for the prevention or treatment of diseases selected from among hypertension, cardiac insufficiency, ischaemic peripheral circulatory disorders, myocardial ischaemia (angina), the progression of cardiac insufficiency after myocardial infarct, diabetic neuropathy, glaucoma, gastrointestinal diseases and bladder diseases, the prevention or treatment of hypertension being particularly preferred. [0053]
  • Accordingly, in another aspect, the present invention is directed to pharmaceutical formulations characterised in that they contain crystalline telmisartan-sodium salt. [0054]
  • The example of synthesis that follows serves to illustrate a method of preparing crystalline telmisartan-sodium salt carried out by way of example. It is intended solely as a possible procedure provided by way of example, without restricting the invention to its contents. [0055]
  • SYNTHESIS EXAMPLE 1 Preparation of Crystalline Telmisartan-Sodium Salt Starting from Telmisartan
  • The starting material used to prepare crystalline telmisartan-sodium salt according to the invention may be the free acid, which may be obtained by methods known from the prior art (e.g. according to EP 502314 A1). [0056]
  • 154.4 g of telmisartan are placed in 308.8 ml of toluene in a suitable reaction vessel. The suspension is combined with 27.8 g of 44.68% sodium hydroxide solution and 84.9 ml of ethanol and heated to 78° C. for about 30 min, then the mixture is filtered. If desired, if large amounts of solid are left in the filter, this may be washed with a mixture of 61.8 ml of toluene and 15.3 ml of ethanol. [0057]
  • 463.2 ml of toluene are placed in another reaction vessel and refluxed. The filtrate obtained by the process described above is slowly added thereto at boiling temperature and simultaneously distilled off azeotropically. After it has all been added the solution which may have been obtained from washing the filter is also added and again distilled off azeotropically. The mixture is distilled at up to 103° C. and the suspension is allowed to cool to ambient temperature. The crystals are suction filtered, washed with 154.4 ml of toluene and dried at 60° C. in the circulating air drier. [0058]
  • Yield: 154.6 g (96%) of colourless crystals; [0059] C33H29N4O2Na × 0.5H2O calc.: C 72.51 H 5.72 N 10.25 found: C 72.57 H 5.69 N 10.21
  • SYNTHESIS EXAMPLE 2 Preparation of Crystalline Telmisartan-Sodium Salt Starting from Telmisartan Hydrochloride
  • A) Preparation of Telmisartan-Hydrochloride: [0060]
  • 411 g of tert.-butyl 4′-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-yl]-methyl]-biphenyl-2-carboxylate are suspended in 822 ml of glacial acetic acid and combined with 213 g of concentrated aqueous hydrochloric acid (37%). The mixture is refluxed and about 640 ml of solvent are distilled off. The residue remaining is slowly combined with about 620 ml of water at 50-60° C. To this mixture are added 20 g of activated charcoal (e.g. Norit SX 2. Ultra) and the resulting mixture is stirred for about 10 min at constant temperature. After filtering, the residue is washed three times with 25 ml of glacial acetic acid and about 620 ml of water. The filtrate obtained is again heated to about 50-60° C. and about 2 L of water are added. After stirring for about 12 hours at about 23° C. the crystals formed are suction filtered and washed twice with about 500 ml of water, once with about 900 ml of acetone and then dried at about 60° C. [0061]
  • Yield: 367 g (92.5%), colourless crystals, melting point: =278° C. [0062]
  • B) Preparation of Crystalline Telmisartan Sodium Salt from Telmisartan Hydrochloride [0063]
  • 55.1 g of telmisartan hydrochloride are taken up in 110.2 ml of toluene, 5.5 ml of water, 55.1 ml of isopropanol and this mixture is combined with 36.9 g of sodium methoxide (30% in methanol) and 2.75 g of activated charcoal (e.g. Sorit SX 2 Ultra). The mixture is then heated to about 75° C., and about 50 ml of solvent mixture are distilled off at constant temperature over about 30 min. The suspension obtained is filtered and the residue is washed with about 20 ml of toluene. The filtrate is combined with about 5 ml of water and about 150 ml of toluene. The mixture obtained is refluxed. During this time about 150 ml of solvent mixture are azeotropically distilled off (at up to 102° C.). The mixture is left to crystallise for one hour at 100° C. The crystals are suction filtered, washed with about 50 ml of toluene and dried at about 60° C. [0064]
  • Yield: 53.6 g (99%), colourless crystals [0065] C33H29N4O2Na.0.5H2O calc.: C 72.51 H 5.72 N 10.25 found: C 72.44 H 5.68 N 10.20
  • To prepare a pharmaceutical composition containing the active substance, particularly an orally administered pharmaceutical composition, most preferably a tablet, procedures known in the art may be used. [0066]
  • Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as maize starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers. [0067]
  • The following are some examples of pharmaceutical preparations which may be used according to the invention. They are intended purely as illustrations by way of example without restricting the subject matter of the invention thereto. [0068] Tablet 1: Ingredients mg Telmisartan-sodium salt hemihydrate 1.00 Mannitol 121.50 Maize starch 79.85 Highly dispersed silicon dioxide, anhydrous 2.30 Polyvidon K25 2.35 Magnesium stearate 3.00 Total 210.00
  • [0069] Tablet 2: Ingredients mg Telmisartan-sodium salt hemihydrate 0.50 Mannitol 122.00 Maize starch, dried 61.80 Maize starch 18.00 Highly dispersed silicon dioxide, anhydrous 2.40 Polyvidon K25 2.30 Magnesium stearate 3.00 Total 210.00
  • [0070] Tablet 3: Ingredients mg Telmisartan-sodium salt hemihydrate 0.25 Mannitol 61.00 Maize starch 39.90 Highly dispersed silicon dioxide, anhydrous 1.20 Polyvidon K25 1.15 Magnesium stearate 1.50 Total 105.00

Claims (3)

What is claimed is:
1. A compound of formula 2
Figure US20040162327A1-20040819-C00005
wherein H—X denotes an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, toluenesulphonic acid and methanesulphonic acid.
2. The compound of formula 2 according to claim 1, wherein H—X denotes hydrogen chloride.
3. A compound according to claim 1 or claim 2, in crystalline form.
US10/777,304 2001-10-31 2004-02-12 Crystalline form of telmisartan sodium Abandoned US20040162327A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE10153737A DE10153737A1 (en) 2001-10-31 2001-10-31 Crystalline sodium salt of telmisartan, process for its preparation and its use for the manufacture of a medicament
DEDE10153737.9 2001-10-31
US35144302P true 2002-01-24 2002-01-24
US10/283,440 US6737432B2 (en) 2001-10-31 2002-10-30 Crystalline form of telmisartan sodium
US10/777,304 US20040162327A1 (en) 2001-10-31 2004-02-12 Crystalline form of telmisartan sodium

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/777,304 US20040162327A1 (en) 2001-10-31 2004-02-12 Crystalline form of telmisartan sodium
US11/462,531 US20060276526A1 (en) 2001-10-31 2006-08-04 Crystalline Form of Telmisartan Sodium

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/283,440 Continuation US6737432B2 (en) 2001-10-31 2002-10-30 Crystalline form of telmisartan sodium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/462,531 Continuation US20060276526A1 (en) 2001-10-31 2006-08-04 Crystalline Form of Telmisartan Sodium

Publications (1)

Publication Number Publication Date
US20040162327A1 true US20040162327A1 (en) 2004-08-19

Family

ID=27214645

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/283,440 Active US6737432B2 (en) 2001-10-31 2002-10-30 Crystalline form of telmisartan sodium
US10/777,304 Abandoned US20040162327A1 (en) 2001-10-31 2004-02-12 Crystalline form of telmisartan sodium
US11/462,531 Abandoned US20060276526A1 (en) 2001-10-31 2006-08-04 Crystalline Form of Telmisartan Sodium

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/283,440 Active US6737432B2 (en) 2001-10-31 2002-10-30 Crystalline form of telmisartan sodium

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/462,531 Abandoned US20060276526A1 (en) 2001-10-31 2006-08-04 Crystalline Form of Telmisartan Sodium

Country Status (1)

Country Link
US (3) US6737432B2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1719766A3 (en) * 2005-05-03 2006-12-20 Dipharma S.p.A. A process for the preparation of telmisartan
ES2296520A1 (en) * 2005-05-18 2008-04-16 Chemagis Ltd. Processes of preparing highly pure telmisartan form A, suitable for pharmaceutical compositions
US20090030057A1 (en) * 2005-11-22 2009-01-29 Shlomit Wizel Pharmaceutical composition of telmisartan
US20090124814A1 (en) * 2004-10-15 2009-05-14 Nurit Perlman Process for preparing telmisartan
US20090227802A1 (en) * 2002-01-16 2009-09-10 Thomas Friedl Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
US7943781B2 (en) 2004-10-18 2011-05-17 Dr. Reddy's Laboratories Limited Process for preparing telmisartan

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737432B2 (en) * 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
DE10314702A1 (en) * 2003-03-31 2004-10-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of telmisartan
US9029363B2 (en) * 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
KR20060054410A (en) * 2003-08-01 2006-05-22 제네랩스 테크놀로지스, 인코포레이티드 Bicyclic imidazol derivatives against flaviviridae
EP1807400A2 (en) * 2004-11-03 2007-07-18 Teva Pharmaceutical Industries, Inc. Amorphous and polymorphic forms of telmisartan sodium
EP1824833A2 (en) * 2004-11-11 2007-08-29 LEK Pharmaceuticals D.D. Preparation of telmisartan salts with improved solubility
WO2006076529A1 (en) * 2005-01-14 2006-07-20 Genelabs Technologies, Inc. Indole derivatives for treating viral infections
US20070116759A1 (en) * 2005-11-22 2007-05-24 Gershon Kolatkar Pharmaceutical compositions of telmisartan
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
KR100893652B1 (en) 2008-11-10 2009-04-17 주식회사종근당 The new telmisartan zinc salt and the preparation thereof
NZ597049A (en) 2009-05-20 2014-01-31 Boehringer Ingelheim Vetmed Pharmaceutical oral telmisartan solution
CA2896646A1 (en) * 2012-12-27 2014-07-03 Hayashibara Co., Ltd. Skin-exterior anti-ageing composition and production method therefor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
US6358986B1 (en) * 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20030130331A1 (en) * 2001-10-31 2003-07-10 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (en) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
DE19901921C2 (en) 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphs of telmisartan, process for their preparation and their use in the manufacture of a medicament

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
US6358986B1 (en) * 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20030130331A1 (en) * 2001-10-31 2003-07-10 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090227802A1 (en) * 2002-01-16 2009-09-10 Thomas Friedl Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
US20090124814A1 (en) * 2004-10-15 2009-05-14 Nurit Perlman Process for preparing telmisartan
US7943781B2 (en) 2004-10-18 2011-05-17 Dr. Reddy's Laboratories Limited Process for preparing telmisartan
EP1719766A3 (en) * 2005-05-03 2006-12-20 Dipharma S.p.A. A process for the preparation of telmisartan
ES2296520A1 (en) * 2005-05-18 2008-04-16 Chemagis Ltd. Processes of preparing highly pure telmisartan form A, suitable for pharmaceutical compositions
US20090030057A1 (en) * 2005-11-22 2009-01-29 Shlomit Wizel Pharmaceutical composition of telmisartan

Also Published As

Publication number Publication date
US20060276526A1 (en) 2006-12-07
US6737432B2 (en) 2004-05-18
US20030130331A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
EP3229799B1 (en) Crystalline forms of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
JP2017128605A (en) Solid forms of antiviral compound
US20180044366A1 (en) Novel crystalline forms of an antiviral benzimidazole compound
EP1658056B1 (en) Tablet containing 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl}-1-methyl-1h-benzimidazolo-5-carbonyl)-pyridino-2-yl- amino]-ethyl propionate or the salts thereof
US8034816B2 (en) Hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
JP4931874B2 (en) Method for producing crystalline polymorph of rimonabant
US20160289192A1 (en) Ivabradine hydrochloride form iv
EP1485094B2 (en) Dosage form for oral administration of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester or its salts
US8563556B2 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one lactic acid salts
EP2060569B1 (en) Ethyl 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionate methanesulfonate hemihydrate and its use as a medicament
TWI404534B (en) Solid pharmaceutical composition comprising amlodipine and losartan with improved stability
DE69811868T2 (en) New crystalline form of omeprazole
KR20080044841A (en) POLYMORPHIC FORMS OF IMATINIB MESYLATE AND PROCESSES FOR PREPARATION OF NOVEL CRYSTALLINE FORMS AS WELL AS AMORPHOUS AND FORM alpha;
US8076362B2 (en) Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof
US6518288B2 (en) Amlodipine fumarate
US20040220212A1 (en) Zolpidem hemitartrate
AU2002307892B2 (en) Crystalline form of omeprazole
ES2339213T3 (en) Amorphous lercanidipine hydrochloride
CN100589802C (en) Pharmaceutical formulation of the sodium salt of telmisartan
EP1910343B1 (en) Process for the preparation of olmesartan medoxomil
US20100273808A1 (en) Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
CN100509789C (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
KR100752549B1 (en) Pseudopolymorphic forms of carvedilol
EP2946772A1 (en) Solid ivabradine-containing composition
US20090042948A1 (en) Physiologically acceptable salts of 3--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION